Stockscreener 앱 받기
25.50
0.16%
0.04
시간 외 거래:
25.50
전일 마감가:
$25.46
열려 있는:
$24.86
하루 거래량:
1.01M
Relative Volume:
1.45
시가총액:
$2.73B
수익:
$14.09M
순이익/손실:
$-176.94M
주가수익비율:
-9.5678
EPS:
-2.6652
순현금흐름:
$-141.24M
1주 성능:
+3.28%
1개월 성능:
+27.44%
6개월 성능:
+48.00%
1년 성능:
+142.86%
1일 변동 폭
$24.55
$26.25
1주일 범위
$24.40
$26.95
52주 변동 폭
$10.50
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
NAMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
25.50 | 2.73B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
Q1 Earnings Estimate for NAMS Issued By Leerink Partnrs - Defense World
(NAMSW) Technical Data - Stock Traders Daily
Nap B.V. Forgrowth Sells 100,728 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
Newamsterdam Pharma sees $4.07 million in stock sales by Forbion funds - Investing.com
What is Leerink Partnrs' Estimate for NAMS Q1 Earnings? - MarketBeat
What is Leerink Partnrs’ Estimate for NAMS Q4 Earnings? - Defense World
Q4 Earnings Forecast for NAMS Issued By Leerink Partnrs - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap DownWhat's Next? - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 4.7%Here's What Happened - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 166,011 Shares - MarketBeat
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg-프린트화면 - The Korea Herald
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg - The Manila Times
NewAmsterdam Pharma (NASDAQ:NAMS) Enters into Underwriting Agreement for Public OfferingNEW YORK–(BUSINESS WIRE)– December 13, 2024– NewAmsterdam Pharma Company N.V. (NAMS) announced today the completion of an underwritten pub - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Short Interest in NewAmsterdam Pharma (NASDAQ:NAMS) Rises By 156.4% - Defense World
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - The Manila Times
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
NewAmsterdam Pharma Secures Massive $479M in Upsized Public Offering, Strengthens Financial Position - StockTitan
NewAmsterdam Pharma’s $452.6M Public Offering Success - TipRanks
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Fmr LLC - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Fmr LLC Buys 86,712 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Newamsterdam Pharma Company (NAMS)Thursday, Sep 12, 2024 - Smartkarma
NewAmsterdam Pharma shares supported by de-risked obicetrapib approval and MACE reduction - Investing.com Canada
NewAmsterdam Pharma (NASDAQ:NAMS) Announces Positive Topline Data from Phase 3 BROADWAY Clinical Trial - Defense World
NewAmsterdam Pharma Launches Massive $416.5M Public Offering with Upsized Share Sale - StockTitan
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - The Manila Times
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 - GlobeNewswire
Shares of New Amsterdam (NAMS) climb after phase III data exceeds expectations - substack.com
NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts (NASDAQ:NAMS) - Seeking Alpha
NewAmsterdam leaps on positive trial results - The Pharma Letter
NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan
NewAmsterdam reports positive Phase 3 trial results for CVD drug By Investing.com - Investing.com South Africa
NewAmsterdam Pharma halts $150 million share sale plan By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma halts $150 million share sale plan - Investing.com India
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - 24matins.uk
NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug - Yahoo! Voices
NewAmsterdam Pharma Announces Commencement of $300 Million - GlobeNewswire
NewAmsterdam Pharma Launches Massive $300M Public Offering with Pre-Funded Warrants - StockTitan
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - AOL
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday - Benzinga
NewAmsterdam reports positive Phase 3 trial results for CVD drug - Investing.com India
NewAmsterdam's drug shows promise in lowering LDL-C - Investing.com
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia - The Manila Times
NewAmsterdam Pharma Announces Positive Topline Data from - GlobeNewswire
NewAmsterdam Pharma's Phase 3 Trial Shows Breakthrough 33% Cholesterol Reduction in Heart Disease Patients - StockTitan
Frazier Life Sciences Management L.P. Buys 628,251 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Janus Henderson Group PLC Boosts Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Walleye Capital LLC Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Grants Inducement Share Options to New Executives Under 2024 Plan - StockTitan
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):